These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

779 related items for PubMed ID: 17898879

  • 1. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
    Franzolini N, Quartuccio L, De Marchi G, De Vita S.
    Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879
    [Abstract] [Full Text] [Related]

  • 2. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [Abstract] [Full Text] [Related]

  • 3. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
    Cavagna L, Caporali R, Abdì-Alì L, Dore R, Meloni F, Montecucco C.
    J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
    [Abstract] [Full Text] [Related]

  • 4. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.
    Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, Amano K, Takeuchi T.
    J Rheumatol; 2005 Sep; 32(9):1719-26. PubMed ID: 16142867
    [Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Scleroderma Lung Study Research Group.
    N Engl J Med; 2006 Jun 22; 354(25):2655-66. PubMed ID: 16790698
    [Abstract] [Full Text] [Related]

  • 7. [The antisynthetase syndrome: a cause of rapidly progressive interstitial lung disease].
    Jordan Greco AS, Métrailler JC, Dayer E.
    Rev Med Suisse; 2007 Nov 21; 3(134):2675-6, 2679-81. PubMed ID: 18159702
    [Abstract] [Full Text] [Related]

  • 8. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset.
    Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, Humbert M, Couderc LJ, Wallaert B, Cadranel J.
    Thorax; 2008 Jan 21; 63(1):53-9. PubMed ID: 17557770
    [Abstract] [Full Text] [Related]

  • 9. [Idiopathic interstitial pneumonia: treatment].
    Cottin V.
    Rev Mal Respir; 2006 Sep 21; 23(4 Pt 2):10S97-10S102. PubMed ID: 17127978
    [No Abstract] [Full Text] [Related]

  • 10. Advances in immunosuppressive therapy.
    Marder W, McCune WJ.
    Semin Respir Crit Care Med; 2007 Aug 21; 28(4):398-417. PubMed ID: 17764058
    [Abstract] [Full Text] [Related]

  • 11. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.
    Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV.
    Arthritis Rheum; 2005 Aug 21; 52(8):2439-46. PubMed ID: 16052580
    [Abstract] [Full Text] [Related]

  • 12. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
    Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, Sierakowski S.
    Ann Rheum Dis; 2005 Sep 21; 64(9):1343-6. PubMed ID: 16100339
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L.
    J Rheumatol; 2008 Jun 21; 35(6):1064-72. PubMed ID: 18464307
    [Abstract] [Full Text] [Related]

  • 14. [Polymyositis and Jo-1 syndrome].
    Treher E, Niederhoff A, Gellissen U, Schmidt P, Dornberg M, Peter HH.
    Z Rheumatol; 1993 Jun 21; 52(5):301-6. PubMed ID: 8259722
    [Abstract] [Full Text] [Related]

  • 15. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
    Colaci M, Sebastiani M, Giuggioli D, Manfredi A, Spagnolo P, Luppi F, Richeldi L, Ferri C.
    Scand J Rheumatol; 2010 Mar 21; 39(2):155-9. PubMed ID: 20059446
    [Abstract] [Full Text] [Related]

  • 16. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
    Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Black CM, du Bois RM, Wells AU.
    Arthritis Rheum; 2007 Jun 21; 56(6):2005-12. PubMed ID: 17530640
    [Abstract] [Full Text] [Related]

  • 17. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia.
    Kondoh Y, Taniguchi H, Yokoi T, Nishiyama O, Ohishi T, Kato T, Suzuki K, Suzuki R.
    Eur Respir J; 2005 Mar 21; 25(3):528-33. PubMed ID: 15738299
    [Abstract] [Full Text] [Related]

  • 18. Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias.
    Churg A, Müller NL, Silva CI, Wright JL.
    Am J Surg Pathol; 2007 Feb 21; 31(2):277-84. PubMed ID: 17255773
    [Abstract] [Full Text] [Related]

  • 19. Antisynthetase syndrome with refractory lung involvement and myositis successfully treated with double filtration plasmapheresis.
    Bozkirli DE, Kozanoglu I, Bozkirli E, Yucel E.
    J Clin Apher; 2013 Dec 21; 28(6):422-5. PubMed ID: 23908096
    [Abstract] [Full Text] [Related]

  • 20. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
    Várai G, Earle L, Jimenez SA, Steiner RM, Varga J.
    J Rheumatol; 1998 Jul 21; 25(7):1325-9. PubMed ID: 9676764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.